Nanofilm FY2025 revenue at S$244.6 million, profit at S$11.9 million on AMBU demand and IEBU recovery

SGX Filings
02/25

Nanofilm Technologies International Limited reported profit after tax of S$11.9 million for the 12 months ended Dec 31 2025, up 58% year-on-year, lifted by sustained growth in its Advanced Materials Business Unit (AMBU) and a rebound in Industrial Equipment sales.

Group revenue rose 20% to S$244.6 million, while adjusted EBITDA increased 21% to S$62.8 million, driving a 30-basis-point improvement in the adjusted EBITDA margin to 25.7%. The board proposed a final dividend of 0.87 Singapore cents a share, bringing the FY2025 payout to 1.20 Singapore cents.

AMBU remained the principal revenue engine, expanding 20% YoY to S$206.9 million on new and existing consumer electronics programmes and contributions from industrial customers in Europe. IEBU revenue surged 50% to S$17.0 million, supported by higher demand for next-generation mould coaters and solar equipment. NFBU recorded modest growth of 0.7% to S$18.2 million, while hydrogen-focused subsidiary Sydrogen posted a 9.8% revenue decline to S$2.5 million as some customer orders were deferred.

Group gross profit margin slipped to 36.2% from 37.1% in FY2024, weighed down by higher interim manpower costs during product ramp-ups; however, second-half GPM rebounded to 38.9% as operations stabilised. Second-half PAT eased 6% YoY to S$10.5 million after a S$3.6 million loss from the closure and write-off of workshops.

Looking ahead, Nanofilm plans to deepen its “China Plus One” manufacturing strategy by expanding capacity in Vietnam and India and broadening its European footprint. Management forecasts balanced growth in the consumer-focused coatings segment, double-digit expansion in industrial and automotive applications, and continued momentum in equipment sales. NFBU is targeting double-digit growth in 2026 on new 3C health-sensing and flash-lens projects, while Sydrogen seeks to scale fuel-cell-related coatings following successful certification tests.

The group said it has largely completed a major capital-expenditure cycle and will prioritise higher utilisation of existing assets, tighter cost controls and improved cash generation, with the overarching objectives of achieving faster revenue growth, stronger profitability and enhanced shareholder returns.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10